Icosapent Ethyl = ↓↓ Inflammation

Health & Wellness, Heart Health

IMG_0371

In an upcoming issue of the American Journal of Cardiology we analyzed the effects of Icosapent Ethyl (Vascepa®) 4 capsules daily for 12 weeks in men and women with elevated levels of triglycerides (200-499 mg/dL) and bodily inflammation (hs-CRP > 2 mg/L).  Healthy levels of triglycerides and hs-CRP are less than 100 mg/dL (fasting) and less than 1 mg/L respectively, whereas high levels of each are independently associated with an increased risk of heart-related complications (such as heart attack or stroke).

Our new study found that Icosapent Ethyl significantly reduced triglycerides (20%) and hs-CRP (18%) in patients at high risk for cardiovascular events, adding to the growing body of evidence in support of this highly effective, safe and unique therapy.

Overall, the unprecedented results from the recently completed REDUCE-IT study that demonstrated robust reductions in major cardiovascular events (25%) and total ischemic events (30%) provide robust support for Icosapent Ethyl in select men and women at increased risk for cardiovascular disease.

Michael Miller, MD is author of the bestselling book Heal Your Heart: The Positive Emotions Prescription to Prevent & Reverse Heart DiseaseProfessor of Cardiovascular Medicine at the University of Maryland School of Medicine in Baltimore, Maryland USA.  

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s